The UK has approved a new treatment for patients with COVID-19 which could allegedly work against the Omicron variant.
The Medicines and Healthcare products Regulatory Agency (MHRA) said Xevudy or sotrovimab is for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
Developed by GSK and Vir Biotechnology, sotrovimab is a single monoclonal antibody that works by binding to the spike protein on the outside of the COVID-19 virus and prevents the virus from attaching to and entering human cells, so that it cannot replicate in the body.
“I am pleased to say that we now have another safe and effective COVID-19 treatment, Xevudy (sotrovimab), for those at risk of developing severe illness, said Dr June Raine, MHRA Chief Executive.
Companies behind Xevudy said preclinical data show sotrovimab retains activity against all tested variants of concern, including key mutations of Omicron.
The UK has also purchased another 114 million COVID-19 vaccines amid growing fear about the fast-spreading Omicron variant.
The country’s Health Secretary Sajid Javid said the “new deals will future-proof the Great British vaccination effort – which has so far delivered more than 115 million first, second, and booster jabs.”
© Fourth Estate
® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.